Penalty Amount
$300,000
Connecticut Attorney General William Tong announced a settlement with international trade platform Made-in-China to cease all U.S. sales of unlawful 'research grade' GLP-1 weight loss drugs following an investigation into direct sales to consumers without prescriptions or medical oversight. The settlement prohibits the platform from hosting GLP-1 sales to U.S. customers, requires a monitoring system to remove non-compliant listings, and imposes a $300,000 penalty suspended after an initial $30,000 payment. Additional settlements were announced with Radiance Medspa and Advanced Medical Weight Loss over compounded non-FDA approved GLP-1 drugs.
Made-in-China must prohibit manufacturers from advertising or selling GLP-1s to U.S. customers, deploy a monitoring system to detect and remove such listings, and remove existing GLP-1 listings within five days. The company is subject to a $300,000 penalty, with $30,000 due initially and the remaining $270,000 suspended; additional penalties apply for settlement violations.
In-house legal teams at online trade platforms and e-commerce vendors should review vendor agreements and terms of service to add explicit prohibitions on selling unapproved FDA-regulated drugs, prescription-only medications, and misbranded health products without valid medical oversight. Contracts should include requirements for automated monitoring systems to detect non-compliant listings, specified timeframes for removing prohibited content, and penalty clauses with suspended amounts that trigger upon breach of terms. Platforms should also include indemnification provisions and audit rights to ensure vendor compliance with health and safety regulations.
Entity
Made-in-China
Industry
Other"05/06/2026"
"Made-in-China"
"$300,000 penalty to the state, suspended after $30,000"
"violations of the Connecticut Unfair Trade Practices Act"
"unlawful sales of bootleg GLP-1 weight loss drugs direct to Connecticut consumers without prescriptions or any medical oversight"
"prohibits manufacturers from using the platform to advertise or sell GLP-1s to customers in the United States"
Connecticut Attorney General William Tong joined other state attorneys general in suing the federal government over deals that canceled offshore wind leases in exchange for payments to Bluepoint Wind and Invenergy. The states allege the deals unlawfully used taxpayer funds and failed to follow required procedures, and ask the courts to invalidate the deals and block their implementation.
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
Connecticut Attorney General William Tong issued a statement regarding a consent decree secured with Warner Bros./Paramount to protect editorial independence of CNN and CBS News. The consent decree establishes an editorial board structure, though the AG expressed disappointment that full divestiture was not achieved.
$694.0M
Connecticut Attorney General William Tong joined 40 other state attorneys general in a settlement with Credit Acceptance Corporation (CAC), one of the nation's largest subprime auto lenders, resolving allegations that CAC originated loans it knew or should have known consumers could not afford and encouraged or failed to prevent dealers from 'packing' CAC loans with unwanted Vehicle Service Contract (VSC) and GAP products. The settlement, announced September 17, 2026 and effective November 2, 2026, directs $694 million in cash restitution and debt relief to consumers, plus an additional $15 million to the states, and imposes injunctive lending reforms. Note: this is a consumer-protection/lending enforcement action rather than a data privacy matter; the violation categories are best-fit mappings to the available taxonomy.
Connecticut Attorney General William Tong issued an advisory that newly enacted privacy laws take effect October 1, 2026, including Public Act 26-64 (SB4), which amends the Connecticut Data Privacy Act, and Public Act 26-15 (SB5), which established the Connecticut Artificial Intelligence Responsibility and Transparency Act (CART Act). The new laws regulate surveillance pricing, facial recognition technology, genetic data collected by direct-to-consumer testing companies, a ban on the sale of precise geolocation data, a data broker registry, AI use in employment decisions, and chatbots offered to children. No enforcement action was taken; this is prospective guidance alerting consumers and businesses to new rights and compliance requirements.
$384.2M
Connecticut joined 39 other states and the federal government in a $384 million False Claims Act settlement with Abbott Laboratories over allegations that the company failed to manufacture powder infant formula and nutritional therapy products in compliance with federal and state requirements at its Sturgis, Michigan, and Casa Grande, Arizona facilities. Abbott allegedly manufactured formula in conditions that risked microorganism contamination and failed to disclose contamination test results to the FDA during 2019 and 2022 inspections. The settlement resolves claims that Abbott caused false claims to be submitted to the WIC program and state Medicaid programs between January 1, 2018, and December 31, 2022.